Implicit to develop ex-Icos antibody for lung injury
This article was originally published in Scrip
Executive Summary
Implicit Bioscience has acquired from Lilly a CD14-targeting antibody, which it will develop as a treatment for acute lung injury (ALI). The US major has received an undisclosed cash payment and has also taken an equity stake in the private Australian firm, which will pay royalties on future sales of the therapy.